Izotropic Publishes New FAQ Page for Investors, Analysts, and Healthcare Decision-Makers
Izotropic Corporation (OTCQB: IZOZF) has launched a new FAQ webpage at www.izocorp.com/faq to enhance transparency and provide comprehensive information about its IzoView Breast CT Imaging System. The resource serves multiple stakeholders including investors, analysts, and healthcare professionals.
The FAQ page covers key topics such as IzoView's advantages over traditional imaging methods (mammography, tomosynthesis, ultrasound, and MRI), breast density's role in cancer detection, and the company's exclusive global commercialization rights for breast CT technology from UC Davis. The page is optimized for search engines and AI platforms to improve visibility across various channels.
- None.
- None.
VANCOUVER, British Columbia, and SACRAMENTO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- via IBN –Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic”, or the “Company”), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the launch of a new Frequently Asked Questions (“FAQ”) page on its corporate website.
The new FAQ resource, available at www.izocorp.com/faq, is designed to improve transparency and provide quick access to essential information on the Company’s flagship device, the IzoView Breast CT Imaging System, the Company’s development milestones, and its competitive positioning in the global breast imaging market.
The page serves as a strategic informational and investor relations tool, delivering clear, accessible content for shareholders, analysts, healthcare professionals, procurement decision-makers, and breast cancer advocates. Topics include how IzoView compares to mammography, tomosynthesis, ultrasound, and MRI; the role of breast density in cancer detection; IzoView’s non-compressive, patient-centered imaging workflow; and Izotropic’s exclusive global rights to commercialize breast CT technology developed at the University of California, Davis.
To support broader awareness and outreach efforts, the page is optimized for search engine indexing and artificial intelligence platforms, improving discoverability across investor, clinical, and media channels.
This resource reflects Izotropic’s ongoing commitment to transparency, strategic communication, and building long-term investor confidence as the Company advances through key milestones in its U.S. clinical study, FDA regulatory process, and commercial rollout.
As interest grows in next-generation imaging solutions for dense breast tissue, breast CT is emerging as a promising new modality. With IzoView uniquely engineered to meet this need through high-resolution, 360-degree, true 3D imaging, the FAQ page will serve as a continually updated reference to support investor engagement, media coverage, and market education.
About Izotropic:
More information about Izotropic Corporation can be found on its corporate website at izocorp.com, its educational website at breastct.com, and by reviewing its profile on SEDAR at sedarplus.ca.
Forward-Looking Statements:
This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words.
These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView has not yet been approved or cleared for sale.
Contacts:
Robert Thast, Interim Chief Executive Officer
Telephone: 1-604-220-5031 or 1-833-IZOCORP ext. 1
Email: bthast@izocorp.com
James Gagnon, International Communications
Telephone: 1-604-780-7576 or 1-833-IZOCORP ext. 2
Email: jgagnon@izocorp.com
General and Corporate Inquiries
Telephone: 1-604-825-4778 or 1-833-IZOCORP ext. 3
Email: info@izocorp.com
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com
FAQ
What is the purpose of Izotropic's (IZOZF) new FAQ page launched in September 2025?
How does Izotropic's IzoView Breast CT system differ from traditional mammography?
What technology rights does Izotropic (IZOZF) hold for breast CT imaging?
What is the current development status of Izotropic's (IZOZF) IzoView system?
